EICHORCondition: Cutaneous Squamous Cell Carcinoma · Sponsor: Regeneron Pharmaceuticals
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objectives of the study are: * To compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from distant recurrence (FFDR) after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on the cumulative incidence of second primary CSCC tumors (SPTs) after surgery and RT * To evaluate the safety of adjuvant cemiplimab and that of placebo in high-risk CSCC patients after surgery and RT * To assess cemiplimab pharmacokinetics and immunogenicity in human serum
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | — |
| Regeneron Study Site | Tucson, Arizona, United States | — |
| The Angeles Clinic | Los Angeles, California, United States | — |
| University of Southern California (USC) | Los Angeles, California, United States | — |
| Stanford Cancer Institute, Stanford Medicine at Stanford University | Palo Alto, California, United States | — |
| University Of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | — |
| George Washington University School of Medicine and Health Sciences | Washington D.C., District of Columbia, United States | — |
| University of Florida Health | Gainesville, Florida, United States | — |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami, Florida, United States | — |
| University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | — |
+ 154 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03969004